International Journal of Nephrology / 2018 / Article / Tab 2

Research Article

Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders

Table 2

Base case input values.

ParameterSevelamerCaCO3UnitSource

Population characteristics
Mean age at baseline57.957.9yearDi Iorio 2012
Baseline serum phosphate level4.824.87mg/dlDi Iorio 2012
CKD stage 35050%Assumption derived from Di Iorio 2012
CKD stage 45050%Assumption derived from Di Iorio 2012

Drug treatment
Sevelamer dose2.184n/ag/dayDi Iorio 2012
CaCO3 dosen/a2.950g/dayDi Iorio 2012
Drug cost5.00690.0871RM/gSevelamer cost: Sanofi, CaCO3 cost: IMS 2013

Efficacy
Survival up to 36 monthsFigure 2Figure 2Modelled from INDEPENDENT-CKD data
Dialysis initiation up to 36 monthsFigure 3Figure 3Modelled from INDEPENDENT-CKD data
Long-term survivalFigure 2Figure 2Modelled from INDEPENDENT-CKD data
Long-term dialysis initiationFigure 3Figure 3Modelled from INDEPENDENT-CKD data

Utility
Pre-dialysis CKD utility0.860.86Gorodetskaya 2005; weighted average of utility in stage 4 and 5 CKD
Dialysis utility0.80.8Bavanandan 2010

Dialysis
Proportion of patients on HD8888%21st MDTR 2013
Proportion of patients on CAPD1212%21st MDTR 2013
HD cost259.09259.09RM/ sessionHooi 2005, IMF 2013
CAPD cost99.0499.04RM/dayHooi 2005, IMF 2013

Base case modelling parameters
Cohort size10001000patientAssumption
Time horizon6060yearAssumption
Discount rate on costs33%Malaysian PE Guidelines 2012
Discount rate on outcomes33%Malaysian PE Guidelines 2012